Triple negative breast cancer (TNBC) is a highly aggressive subset of invasive breast cancer, accounting for approximately 15% of all cases and defined by lack of estrogen receptor, progesterone receptor, and HER2. Improvements in the treatment of TNBC patients will likely come from identifying the oncogenes critical to the development and maintenance of TNBC. Most importantly, new therapies must treat not only the proliferative population of tumor cells, but also latent populations of disseminated tumor initiating cells, which are hypothesized to be responsible for recurrence and metastasis. Our past work has established important roles for cell cycle regulatory proteins in the initiation and proliferation of tumors in the mammary gland, with an emphasis on the low molecular weight forms of cyclin E (LMW-E). Recent work in our laboratory has demonstrated that LMW-E forms are overexpressed in 70% of TNBCs and correlates with poor prognosis in these patients. We identified novel ways in which LMW-E functions beyond tumor initiation and deregulated proliferation, demonstrating that LMW-E has a role tumor progression. Specifically, we have identified roles for LMW-E in the initiation of the epithelial-mesenchymal transition (EMT), generation of metastases in transgenic mice, and enrichment of a tumor initiating population of cells. The next challenge is to develop a mechanistic understanding of LMW-E in these processes and determine the feasibility of therapeutic attenuation of LMW-E activity in blocking tumor progression. However, we do not know if deregulation of pathways upstream of EL cyclin E is the initiating event. One of the key proteins that is upstream of cyclin E is elastase, which cleaves EL cyclin E to generate LMW-E. An unanswered question is if the deregulation of elastase in tumor cells is sufficient to generate LMW-E giving rise to the transformed phenotype. The central hypothesis of the proposed research is that proteolytic processing of EL cyclin E to LMW-E by elastase predisposes mammary epithelium to oncogenesis by altering cyclin E interacting partners and substrates and aberrantly activating signaling pathways that lead to induction of the EMT and cells with tumor initiating potentials. The following aims are designed to test each aspect of this hypothesis:
Aim 1 : Determine the requirement of LMW-E timing and expression for tumor maintenance and recurrence in an inducible transgenic mouse model and correlate with TNBC patients.
Aim 2 : Investigate the role of proteolytic processing of full length cyclin E to LMW-E by elastase in mammary tumorigenesis.
Aim 3 : Examine the mechanism of LMW-E mediated oncogenecity through identification and characterization of novel binding proteins and substrates for cytoplasmic LMW-E The successful completion of these studies will develop a mechanistic view of consequences of LMW-E expression in tumorigenesis and translate our findings to clinic. Additionally, our mouse model system will provide us with a unique system to examine the effectiveness of novel therapeutics targeted to TNBC in a preclinical in vivo setting.

Public Health Relevance

The information gained through the proposed studies could have tremendous clinical relevance for patients with triple negative breast cancer. We already know that LMW-E expression correlates with poor TNBC patient outcome;elucidating how the LMW-E expression can also alter the cytoplasmic signal transduction pathways which could then lead to EMT and tumorigenesis, will open novel avenues of cancer therapy that can take advantage of treatment strategies targeting LMW-E. As such, a targeted and personalized therapy can be justified for those patients who currently do not have such treatment strategies available to them.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA087548-13
Application #
8585030
Study Section
Molecular Oncogenesis Study Section (MONC)
Program Officer
Hildesheim, Jeffrey
Project Start
2000-07-01
Project End
2015-11-30
Budget Start
2014-01-07
Budget End
2014-11-30
Support Year
13
Fiscal Year
2014
Total Cost
$257,865
Indirect Cost
$94,659
Name
University of Texas MD Anderson Cancer Center
Department
Radiation-Diagnostic/Oncology
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Pickering, Curtis R; Bast Jr, Robert C; Keyomarsi, Khandan (2015) How will we recruit, train, and retain physicians and scientists to conduct translational cancer research? Cancer 121:806-16
Caruso, J A; Akli, S; Pageon, L et al. (2015) The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene 34:3556-67
Murray, Mollianne McGahren; Bui, Tuyen; Smith, Michelle et al. (2013) Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis 34:2244-52
Duong, Mylinh T; Akli, Said; Macalou, Sira et al. (2013) Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells. Cancer Res 73:5556-68
Akli, Said; Zhang, Xin-Qiao; Bondaruk, Jolanta et al. (2012) Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle 11:1468-76
Duong, MyLinh T; Akli, Said; Wei, Caimiao et al. (2012) LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet 8:e1002538
Akli, Said; Van Pelt, Carolyn S; Bui, Tuyen et al. (2011) Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res 71:3377-86
Keyomarsi, Khandan; Efuet, Ekem T; Bui, Tuyen N (2011) Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells. Cell Biol Toxicol 27:123-31
Mittendorf, E A; Liu, Y; Tucker, S L et al. (2010) A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 29:3896-907
Akli, Said; Bui, Tuyen; Wingate, Hannah et al. (2010) Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res 16:1179-90

Showing the most recent 10 out of 26 publications